Sphingosine kinase 2 prevents the nuclear translocation of sphingosine 1-phosphate receptor-2 and tyrosine 416 phosphorylated c-Src and increases estrogen receptor negative MDA-MB-231 breast cancer cell growth : the role of sphingosine 1-phosphate receptor-4 by Ohotski, Jan et al.
Strathprints Institutional Repository
Ohotski, Jan and Rosen, Hugh and Bittman, Robert and Pyne, Susan and 
Pyne, Nigel J (2014) Sphingosine kinase 2 prevents the nuclear 
translocation of sphingosine 1-phosphate receptor-2 and tyrosine 416 
phosphorylated c-Src and increases estrogen receptor negative MDA-
MB-231 breast cancer cell growth : the role of sphingosine 1-phosphate 
receptor-4. Cellular Signalling, 26 (5). pp. 1040-1047. ISSN 0898-6568 , 
http://dx.doi.org/10.1016/j.cellsig.2014.01.023
This version is available at http://strathprints.strath.ac.uk/49212/
Strathprints is  designed  to  allow  users  to  access  the  research  output  of  the  University  of 
Strathclyde. Unless otherwise explicitly stated on the manuscript, Copyright © and Moral Rights 
for the papers on this site are retained by the individual authors and/or other copyright owners. 
Please check the manuscript for details of any other licences that may have been applied. You 
may  not  engage  in  further  distribution  of  the  material  for  any  profitmaking  activities  or  any 
commercial gain. You may freely distribute both the url (http://strathprints.strath.ac.uk/) and the 
content of this paper for research or private study, educational, or not-for-profit purposes without 
prior permission or charge. 
Any  correspondence  concerning  this  service  should  be  sent  to  Strathprints  administrator: 
strathprints@strath.ac.uk
 
Sphingosine kinase 2 prevents the nuclear translocation of sphingosine 1-phosphate receptor-2 
and tyrosine 416 phosphorylated c-Src and increases estrogen receptor negative MDA-MB-231 
breast cancer cell growth: The role of sphingosine 1-phosphate receptor-4 
 
Jan Ohotski‡, Hugh Rosen//, Robert Bittman†, Susan Pyne,‡ Nigel J. Pyne‡* 
 
‡Cell Biology Group, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of 
Strathclyde, Glasgow G4 0RE, United Kingdom 
 
†Department of Chemistry and Biochemistry, Queens College, The City University of New York, 
Flushing, New York 11367-1597, United States 
 
// The Scripps Research Institute, Department of Chemistry, 10550 N. Torrey Pines Rd, La Jolla, CA 
92037, USA 
 
* To whom correspondence should be addressed (n.j.pyne@strath.ac.uk) 
 
 
 
 
 
 
 
 
 
 
ABSTRACT--We demonstrate that pre-treatment of estrogen receptor negative MDA-MB-
231 breast cancer cells containing ectopically expressed HA-tagged sphingosine 1-phosphate 
receptor-2 (S1P2) with the sphingosine kinase 1/2 inhibitor SKi (2-(p-hydroxyanilino)-4-(p-
chlorophenyl)thiazole) or the sphingosine kinase 2 selective inhibitor (R)-FTY720 methyl 
ether (ROMe) or sphingosine kinase 2 siRNA induced the translocation of HA-tagged S1P2 
and Y416 phosphorylated c-Src to the nucleus of these cells.  This is associated with reduced 
growth of HA-tagged S1P2 over-expressing MDA-MB-231 cells.  Treatment of HA-S1P2 over-
expressing MDA-MB-231 cells with the sphingosine 1-phosphate receptor-4 (S1P4) antagonist 
CYM50367 or with S1P4 siRNA also promoted nuclear translocation of HA-tagged S1P2. 
These findings identify for the first time a signalling pathway in which sphingosine 1-
phosphate formed by sphingosine kinase 2 binds to S1P4 to prevent nuclear translocation of 
S1P2 and thereby promote the growth of estrogen receptor negative breast cancer cells. 
 
Keywords: Sphingosine 1-phosphate, Sphingosine 1-phosphate receptors, Sphingosine kinase, 
Cancer, Growth, Nuclear Signalling  
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
The bioactive lipid sphingosine 1-phosphate (S1P) is derived from the phosphorylation of 
sphingosine catalyzed by the two isoforms of sphingosine kinase (SK1 and SK2) and is cleaved by 
S1P lyase or dephosphorylated by S1P phosphatases [1-3].  S1P binds to S1P-specific G-protein 
coupled receptors termed S1P1-5 and also interacts with intracellular protein targets, such as 
TRAF2 [1, 4].  There is now a wealth of evidence to support a role of S1P in cancer progression 
[5].  For instance, S1P stimulates migration of gastric tumor cells that exclusively express S1P3 
and inhibits the motility of others that predominantly express S1P2 [6].  Similarly, the S1P-
dependent inhibition of melanoma cell migration is mediated by S1P2 via inhibition of Rac, 
activation of Rho, and tyrosine phosphorylation of focal adhesion kinase [7].  High tumor nuclear 
expression of both c-Src and S1P2 is also associated with longer disease-specific survival time in 
breast cancer [8].  S1P also induces connective tissue growth factor (CTGF) expression in the 
Wilms’ tumor cell line, WiT49, which expresses S1P2 [9].  However, FTY720-phosphate, which 
binds to S1P1/3/4/5, but not to S1P2 [10], fails to induce CTGF expression, suggesting that the 
receptor involved is S1P2.  Indeed, S1P-stimulated CTGF expression is abolished by the S1P2/4 
antagonist JTE-013 and increased by over-expression of S1P2 [9].  S1P binding to S1P2 stimulates 
CTGF expression by the JNK- and Rho kinase-dependent pathways and CTGF expression is 
reduced in Wilms’ tumors.  In addition, over-expression of CTGF inhibits proliferation of WiT49 
cells, suggesting that CTGF expression induced by S1P2 is a growth inhibitor of Wilms’ tumor [9]. 
 
However, S1P2 has also been shown to promote cancer progression.  For instance, S1P binding to 
S1P2 increases invasiveness of glioma by a mechanism involving enhanced expression of the 
secreted, angiogenic matricellular protein CCN1/Cyr61 [11].  Recently, Ponnusamy et al. [12] 
demonstrated that systemic S1P, produced by the host SK1, promotes lung colonization and 
metastasis by a mechanism involving S1P2.  The reduction in systemic S1P inhibits TRAMP-
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induced prostate cancer growth in TRAMP+/+Sk1-/- mice or lung metastasis of various cancer cells 
in Sk1-/- mice.  SK1 loss promotes the expression of breast carcinoma metastasis suppressor 1 
(Brms1), and S1P binding to S1P2 reduces Brms1 expression in these cancer cells [12].  Binding of 
S1P to S1P2 induces phosphorylation of ERM proteins, which is linked with filopodia formation in 
cancer cells [13].  SK1/S1P has also been shown to enhance Bcr-Abl1 protein stability via a S1P2-
dependent mechanism [14].  In this mechanism, S1P formed by SK1 is released to act on S1P2, 
which inactivates PP2A and thereby prevents Bcr-Abl1 degradation [14].  Therefore, the precise 
role of S1P2 in cancer remains controversial. 
 
We have reported that high tumor S1P4 expression is associated with shortened disease-specific 
survival and recurrence times in patients with estrogen receptor negative tumors [15].  High S1P4 
expression is also correlated with node positive status, suggesting a role for this receptor in 
metastasis.  Therefore, S1P4 is an important biomarker for prognostic outcome in estrogen receptor 
negative breast cancer [16], providing a strong rationale for targeting this receptor with new 
chemotherapeutic anti-cancer agents.  We have also reported that human epidermal growth factor 
receptor 2 (HER2)/ErbB2 functionally interacts with S1P4 in estrogen receptor negative MDA-
MB-453 breast cancer cells [17].  S1P binding to S1P4 stimulates activation of ERK-1/2, which 
involves transactivation of HER2 [17].  The functional interaction of S1P4 with this oncogene 
provides additional evidence that S1P4 plays an important role in estrogen receptor negative breast 
cancer progression.   
 
We demonstrate here that SK2 and S1P/S1P4 normally functions to prevent nuclear translocation 
of S1P2.  These findings represent a hitherto unidentified functional interaction between SK2 and 
S1P4 and demonstrate that the sub-cellular distribution of S1P2 has a critical impact on cancer cell 
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growth.  These findings might account for some of the conflicting reports about the function of 
S1P2 in cancer. 
 
MATERIALS AND METHODS 
All biochemicals were from Sigma-Aldrich (Poole, UK).  Anti-HA, anti-Src, and anti-GAPDH 
antibodies were from Santa Cruz Biotechnology (California, USA).  Anti-actin and conjugated 
anti-IgG secondary antibodies were from Sigma (Poole, UK).  Anti-phospho-Src (Y416) and anti-
Lamin A/C antibodies were from Cell Signalling Technology (Massachusetts, USA).  S1P was 
from Avanti Polar Lipids (Alabaster, AL, USA).  SKi ((2-(p-hydroxyanilino)-4-(p-
chlorophenyl)thiazole)) was from Merck Biosciences (Nottingham, UK).  CAY10444 was from 
Cayman Chemical (Michigan, USA).  JTE-013 was from Tocris Bioscience (Abingdon, UK).  
ROMe, RB-005, and 55-22 were synthesized as described previously [18-20]. 
 
Cell Culture--MDA-MB-231 was purchased from ATCC.  The breast carcinoma MCF-7 cell line 
was a gift from Dr Rachel Schiff (Baylor College of Medicine, TX, USA).  Cells were cultured in 
high-glucose Dulbecco’s modified Eagle’s medium (Invitrogen, Paisley, UK) supplemented with 
10% (v/v) European fetal calf serum (Seralab, West Sussex, UK), 100 U/ml penicillin G sodium, 
and 10 Pg/ml streptomycin sulfate (Pen-Strep, Gibco, Paisley, UK).  Cells were maintained at 37 
oC in 95% air and 5% CO2.  All compounds were used at 10 PM, except for S1P, which was used 
at 5 PM.  After transfection for 24 h, the compounds were added for 4 h.  S1P was added after 3 h 
and the duration of stimulation was 1 h. 
 
siRNA Treatment--Cellular expression of SK1, SK2, S1P3, and S1P4 was reduced using sequence-
specific siRNAs.  Scrambled siRNA was used as a control.  Cells were transfected with 100 nM 
siRNA prepared in culture medium containing the DharmaFECT 2 reagent (Invitrogen, Paisley, 
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UK).  The cells were transfected for 24 h and then serum starved for 24 h prior to treatment with 
the compounds.  
 
Transfection--Cells at 80% confluence were transiently transfected with either HA-S1P2 construct 
or pcDNA3.1 vector.  Cells were incubated in serum-free high-glucose Dulbecco’s modified 
Eagle’s medium and transfected using Lipofectamine 2000 (Invitrogen, Paisley, UK) according to 
the manufacturer's instructions. After a 24 h incubation, the cell culture medium was replaced with 
serum-free high glucose Dulbecco’s modified Eagle’s medium prior to treatment with the 
compounds. 
 
Cell Lysate Preparation--Cells were harvested in SDS-PAGE sample buffer containing 125 mM 
Tris/HCl (pH 6.7), 0.5 mM Na4P2O7, 1.25 mM EDTA, 50 mM DTT, 0.5% (w/v) sodium dodecyl 
sulfate, 0.06% (w/v) bromophenol blue, and 1.25% (v/v) glycerol.   
 
Nuclei Preparation--Cells were scraped in 4 ml of phosphate buffered saline (PBS). The cell 
suspensions were transferred into 15-ml centrifuge tubes and pelleted at 700×g for 5 min.  Cell 
nuclei were isolated using the FractionPREP Cell Fractionation kit (BioVision, California, USA).  
Nuclei preparations were mixed with SDS-PAGE sample buffer and processed for western 
blotting. 
 
Western Blotting--Proteins were separated using SDS-PAGE and transferred to a hybond ECL 
nitrocellulose membrane (GE Healthcare, Buchinghamshire, UK).  Membranes were blocked in 
2% (w/v) bovine serum albumin (BSA) (Thermo Fisher Scientific, Massachusetts, USA) in TBST 
buffer (20 mM Tris/HCl (pH 7.5), 48 mM NaCl, and 0.1% (v/v) Tween 20) for 1 h at room 
temperature.  Primary antibody was diluted in TBST buffer and incubated with membranes for 24 
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h at 4oC.  HRP-conjugated anti-mouse or rabbit antibodies diluted in TBST buffer were used to 
detect the primary antibody.  Membranes were incubated with secondary antibody for 1 h at room 
temperature.  A luminol-based enhanced chemiluminescence method was used to visualize the 
immunoreactive protein bands.  
 
Densitometry--Densitometric analysis of western blots was performed using ScanImage (Scion 
Corporation, MD, USA).  Unpaired Student’s t-test was used for statistical analysis. 
 
RT-PCR--Total RNA was isolated from MDA-MB-231 cells using ISOLATE II RNA mini kit 
(Bioline Reagents, London, UK), according to the manufacturer’s instructions. cDNA was 
synthesized from extracted RNA using BioScript (Bioline Reagents, London, UK).  The 
polymerase chain reaction was used to determine the expression levels of SK1, SK2, S1P3, and 
S1P4. The following primers were used: GAPDH (forward: 
TGAAGGTCGGAGTCAACGGATTTGGC, reverse: CATGTGGGCCATGAGGTCCACCAC), 
SK1 (forward: CTGTCACCCATGAACCTGCTGTC, reverse: 
CATGGCCAGGAAGAGGCGCAGCA), SK2 (forward: 
GCCTACTTCTGCATCTACACCTACC, reverse: GAGGTTGAAGGACAGCCCAGCTTC), 
S1P3 (forward: GACTGCTCTACCATCCTGCCC, reverse: GTAGATGACCGGGTTCATGGC) 
and S1P4 (forward: GGCACAGCCGGCTCATTGTT, reverse: 
AAGCTGAGCACGGCTCTGCACA).  Amplification reactions were for 30 cycles, starting with 
denaturation for 30 s at 94 oC, annealing for 1 min at 56 oC, and extension for 1 min at 72 oC, 
performed using the ABI Model 7300 PCR machine. 
 
xCELLgence Assay--The growth of MDA-MB-231 cells was monitored using the xCELLigence 
system.  Cells were plated in 96 wells E-plates (Acea Biosciences, CA, USA) and incubated for 24 
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h at 37oC.  Cells were transfected for 24 h as described before, and the cell culture medium was 
changed prior to treatment with the compounds for 4 h.  After S1P was added after 3 h, the cells 
were incubated for 1 h.  Cell index was measured and recorded using the xCELLigence software 
(Acea Biosciences, CA, USA).  
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RESULTS  
Effect of SK1/SK2 Inhibitor on S1P2 Subcellular Localization--First, we established the sub-
cellular distribution of ectopically expressed HA-tagged S1P2 (HA-S1P2) in estrogen receptor 
negative MDA-MB-231 breast cancer cells. HA-S1P2 was present in nucleus of untreated cells 
(Fig. 1A) and migrated on SDS-PAGE as two immunoreactive protein bands that sometimes are 
smeared, indicative of post-translation modification, e.g. glycosylation.  There is, in fact, 
substantial evidence demonstrating that GPCRs, including S1P1, are localized in the nucleus of 
cells [21-23] and that the nuclear lysophosphatidic acid receptor-1 (LPA1) can induce PI3K-
mediated signalling to regulate inflammatory gene expression [24, 25].  
 
We next investigated whether SK regulates the nuclear localization of HA-S1P2.  Surprisingly, pre-
treatment of MDA-MB-231 cells with the SK1/2 inhibitor, SKi increased the amount of HA-S1P2 
in the nucleus by 150 % (Fig. 1A, Suppl Fig. 1).  SKi had no effect on the total expression level of 
HA-S1P2 in MDA-MB-231 cells (Fig. 1B).  This excludes changes in expression of HA-S1P2 as a 
possibility that might have accounted for the increase in nuclear HA-S1P2 levels in response to 
SKi.  Therefore, SK normally functions to prevent the nuclear localization of S1P2.  We also found 
that Y416 phosphorylated c-Src was present in the nucleus and that treatment of cells with SKi 
increased the amount of this phosphorylated protein in the nucleus (Fig. 1A, and Suppl Fig. 1).  
Treatment of HA-S1P2 over-expressing MDA-MB-231 cells with S1P reduced the amount of HA-
S1P2 and Y416 phosphorylated c-Src that accumulates in the nucleus in response to SKi (Fig. 1A, 
Suppl Fig. 1).  The nuclear localization of Y416 phosphorylated c-Src has been reported before 
[26], and has been shown to induce export of the anti-oxidant protein Nrf2 to the cytoplasm where 
it is degraded by the proteasome [26].  However, we were unable to detect nuclear export of Nrf2 
in response to SKi (data not shown).   
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Treatment of MDA-MB-231 over-expressing HA-S1P2 with SKi failed to increase the 
phosphorylation of c-Src on Y416 above basal levels, detected in whole cell lysates (Fig. 1B, 
Suppl Fig. 2).  This suggests that SK normally suppresses the translocation of a small pool of c-Src 
that is phosphorylated on Y416 to the nucleus.  Furthermore, treatment of vector-transfected 
MDA-MB-231 cells (that lack ectopically expressed HA-S1P2) with SKi promoted the nuclear 
translocation of c-Src that was not phosphorylated on Y416 (Fig. 1C, Suppl Fig. 3).  This contrasts 
with MDA-MB-231 cells expressing HA-S1P2, where the Y416 phosphorylated form of c-Src 
accumulates in the nucleus in response to SKi, and this therefore appears dependent on the 
presence of HA-S1P2.   
 
In addition, SK, S1P2, and Y416 phosphorylated Src do not functionally interact in estrogen 
receptor positive MCF-7 cells over-expressing HA-S1P2.  Thus, SKi failed to promote an increase 
in the nuclear content of HA-S1P2 or Y416 phosphorylated c-Src in these cells (Fig. 1D, Suppl Fig. 
4).  This suggests that the presence of the estrogen receptor might prevent the functional 
interaction between SIP2 and SK.   
 
SK2 Regulates the Nuclear Translocation of HA-S1P2 and Y416 Phosphorylated c-Src--We next 
investigated whether the nuclear localization of HA-S1P2 and Y416 phosphorylated c-Src is 
regulated by SK1 or SK2 or both.  For this purpose, we used the SK1-selective inhibitors, 55-22 
and RB-005, both of which failed to mimic the effect of SKi in promoting the nuclear translocation 
of HA-S1P2 and Y416 phosphorylated c-Src in HA-S1P2 over-expressing MDA-MB-231 cells 
(Fig. 2A, B, Suppl Fig. 5A, B).  Moreover, siRNA knockdown SK1 failed to induce the nuclear 
accumulation of HA-S1P2 and Y416 phosphorylated c-Src in these cells (Fig. 2C, Suppl Fig. 5C).   
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The treatment of HA-S1P2 over-expressing MDA-MB-231 cells with the SK2-selective inhibitor 
(R)-FTY720 methyl ether (ROMe) or siRNA knockdown of SK2 induced the nuclear 
accumulation of HA-S1P2 and Y416 phosphorylated c-Src (Fig. 1C, Fig. 2D, E, Suppl Fig. 5D, E).  
Furthermore, treatment of these cells with S1P reduced the amount of HA-S1P2 in the nucleus in 
response to ROMe but not SK2 siRNA (Fig. 2D, Suppl Fig. 5D).  ROMe did not increase the 
phosphorylation of c-Src on Y416, and had no effect on HA-S1P2 expression levels in whole cell 
lysates (Fig. 2F, Suppl Fig. 6).  The latter finding excludes changes in expression of HA-S1P2 as a 
possibility that might have accounted for the increase in nuclear HA-S1P2 levels in response to 
ROMe.  In contrast with SKi, S1P failed to reverse the effect of ROMe or SK2 siRNA on the 
translocation of Y416 phosphorylated c-Src (Fig. 2D, E, Suppl Fig. 5D, E). 
 
Influence of S1P4 on the Nuclear Translocation of S1P2 and Y416 Phosphorylated c-Src--The 
ability of exogenous S1P to prevent the SKi- and ROMe-induced nuclear translocation of HA-S1P2 
suggests a role for other S1P receptors in regulating the localization of S1P2 in these cells.  For 
instance, SK2 might be functionally linked with S1P receptors by producing S1P that can be 
released (‘inside-out’ signalling) from the cells to bind to these receptors and prevent nuclear 
accumulation of HA-S1P2.  Therefore, we used pharmacological sub-type selective S1P receptor 
antagonists and siRNA approaches to establish the effect of other S1P receptors on the nuclear 
translocation of HA-S1P2 and Y416 phosphorylated c-Src in MDA-MB-231 cells.  In this regard, 
the S1P2/4 antagonist JTE-013 [17, 27], the S1P3 antagonist CAY10444 [28], or S1P3 siRNA had 
no effect on the nuclear accumulation of HA-S1P2 and Y416 phosphorylated c-Src (Fig. 3A-C, 
Suppl Fig. 7A-C).  However, the S1P4 antagonist CYM50367 [29] promoted the accumulation of 
HA-S1P2, but not Y416 phosphorylated c-Src, in the nucleus (Fig. 3D, Suppl Fig. 7D).  In 
addition, exogenous S1P, which can compete with CYM50367 for S1P4, reduced the amount of 
HA-S1P2 in the nucleus in response to CYM50367 (Fig. 3D, Suppl Fig. 7D).  siRNA knockdown 
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of S1P4 also recapitulated the effect of CYM50367 in promoting the accumulation of HA-S1P2 in 
the nucleus (Fig. 3E, Suppl Fig. 7E).  siRNA knockdown of S1P4 had no effect on HA-S1P2 
expression in whole cell lysates (Fig. 3F), thereby excluding changes in expression of HA-S1P2 as 
a possibility that might have accounted for the increase in nuclear HA-S1P2 levels in response to 
S1P4 siRNA.   
 
Interestingly, S1P was unable to reduce the amount of HA-S1P2 that accumulated in the nucleus in 
response to S1P4 siRNA (Fig. 3E, Suppl Fig. 7E), suggesting that the inhibitory effect of S1P on 
the nuclear accumulation of HA-S1P2 is mediated by S1P4.  Therefore, these results demonstrate 
that S1P2 translocation to the nucleus is regulated by an autocrine loop involving S1P and S1P4.  In 
contrast, the translocation of Y416 phosphorylated c-Src to the nucleus appears to be regulated by 
a mechanism that does not involve S1P3 or S1P4.   
 
Role of Nuclear Translocation of S1P2 and Y416 Phosphorylated c-Src in Regulating MDA-MB-
231 Cell Growth--We next investigated the effect of over-expressing HA-S1P2 on the growth of 
MDA-MB-231 cells treated with the various inhibitors or siRNA knockdown of SK1 or SK2.  
Treatment of HA-S1P2 over-expressing MDA-MB-231 cells with SKi, ROMe, CYM50367, or 
SK2 siRNA induced a reduction in growth; this effect was stronger compared with the effect of 
these compounds or SK2 siRNA in vector-transfected MDA-MB-231 cells (Fig. 4).  JTE-103, 
CAY10444, SK1 siRNA, 55-22, and RB-005 reduced growth, but there was no discernible 
difference between HA-S1P2 or vector-transfected cells (Fig. 4).  These findings are consistent 
with the possibility that SK2 but not SK1 or S1P3 limits translocation of S1P2 and Y416 
phosphorylated c-Src to the nucleus to promote the growth of MDA-MB-231 cells.   
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DISCUSSION 
A model for the functional interaction between S1P4, S1P2, SK2 and Y416 phosphorylated c-Src in 
estrogen receptor negative breast cancer cells is shown in Fig. 5.  Our findings suggest a role for 
S1P formed by SK2, which binds to S1P4 to prevent nuclear translocation of S1P2 and to promote 
the growth of estrogen receptor negative breast cancer cells (Fig. 5A).  One possible model might 
involve heterodimerisation of S1P2 and S1P4 at the plasma membrane in response to S1P and 
which would prevent translocation of S1P2 to the nucleus.  Production of S1P by SK2 or 
exogenously added S1P would maintain this state, while inhibition of SK2 might induce 
dissociation due to reduced S1P levels; enabling S1P2 to move to the nucleus.   Indeed, 
exogenously added S1P reverses the effect of SKi or ROMe on the nuclear translocation of HA-
S1P2, and this is likely mediated by activation of S1P4.  Surprisingly, S1P failed to reverse the 
effect of SK2 siRNA, although it is possible that knockdown of SK2 might affect S1P4 expression.  
Further studies are necessary to establish if this is indeed, the case.  There is a precedent, as we 
have shown that siRNA knockdown of SK1 reduces S1P3 expression in MCF-7 cells [30].   
 
SK2 also prevents the nuclear translocation of Y416 phosphorylated c-Src and this appears to be 
independent of S1P4 and might involve an intracellular S1P-dependent mechanism, which is 
resistant to exogenously added S1P (Fig. 5B).  However, exogenously added S1P did block the 
effects of SKi on nuclear translocation of Y416 phosphorylated c-Src.  Therefore, the effects of 
SKi are not fully recapitulated by ROMe and suggest that additional unidentified mechanisms 
might operate to regulate the translocation of Y416 phosphorylated c-Src to the nucleus in 
response to SKi.   
 
The novel pathways identified here represent a therapeutic target for intervention in estrogen 
receptor negative breast cancer.  This is specifically aimed at abrogating the function of S1P4 and 
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SK2 to promote nuclear translocation of S1P2 and Y416 phosphorylated c-Src and to therefore 
reduce the growth of estrogen receptor negative breast cancer cells.   
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FIGURE LEGENDS 
 
FIGURE 1.  Effects of SKi on the nuclear translocation of S1P2 and Y416 
phoshorylated c-Src.  Vector- or HA-S1P2-transfected MDA-MB-231 or MCF-7 cells were 
treated with SKi (10 PM) for 4 h and with S1P (5 PM) in the last 1 h. (A) Nuclei preparations were 
western blotted with anti-HA, anti-c-Src, anti-Y416 phosphorylated c-Src, and anti-lamin 
antibodies.  The western blot shows the nuclear translocation of HA-S1P2 and Y416 
phosphorylated c-Src in response to SKi in MDA-MB-231 cells.  Also shown are western blots 
with anti-lamin (a nuclear marker) and anti-GAPDH (a cytoplasmic marker) antibodies to verify 
the purity of the nuclei preparation. (B)  MDA-MB-231 whole cell lysates were western blotted 
with anti-HA, anti-c-Src, anti-Y416 phosphorylated c-Src, and anti-actin antibodies.  The western 
blot demonstrates that treatment of cells with SKi failed to increase the phosphorylation of c-Src 
on Y416 in HA-S1P2-transfected and vector-transfected cells. (C)  Nuclei preparations were 
western blotted with anti-c-Src, anti-Y416 phosphorylated c-Src, and anti-lamin antibodies.  The 
western blot shows that that treatment of cells with SKi promotes nuclear translocation of non-
phosphorylated c-Src in vector-transfected MDA-MB 231 cells. (D)  Nuclei preparations of MCF-
7 cells were western blotted with anti-Y416 phosphorylated c-Src and anti-lamin antibodies.  The 
western blot shows that treatment of MCF-7 cells with SKi fails to induce the nuclear translocation 
of HA-S1P2 and Y416 phosphorylated c-Src.  These are representative results of three different 
preparations of cells.    
 
FIGURE 2.  Effects of SK1 and SK2 inhibitors and specific siRNA on the nuclear 
translocation of S1P2 and Y416 phoshorylated c-Src.  Vector- or HA-S1P2-transfected MDA-
MB-231 were treated with 55-22, RB-005, or ROMe (all at 10 PM) for 4 h and with S1P (5 PM) in 
the last 1 h or with scrambled or SK1 or SK2 specific siRNA according to the methods with 
 
subsequent addition of S1P for 1 h. (A-E)  Nuclei preparations were western blotted with anti-HA, 
anti-c-Src, anti-Y416 phosphorylated c-Src, and anti-lamin antibodies.  The western blots show the 
failure of RB-005 (A), 55-22 (B), and SK1 siRNA (C) to induce nuclear translocation of HA-S1P2 
and Y416 phosphorylated c-Src.  In (C), the inset shows successful knock down of SK1 mRNA 
with SK1 siRNA as assessed by RT-PCR analysis. (D and E) Western blots show nuclear 
translocation of HA-S1P2 and Y416 phosphorylated c-Src in response to ROMe (D) and SK2 
siRNA (E), respectively, and inhibition of the effects of ROMe with S1P (D).  In (E), the inset 
shows successful knock down of SK2 mRNA with the SK2 siRNA as assessed by RT-PCR 
analysis. (F)  MDA-MB-231 whole cell lysates were western blotted with anti-Y416 
phosphorylated c-Src, anti-HA, and anti-actin antibodies.  The western blot demonstrates that 
ROMe fails to increase the phosphorylation of c-Src on Y416 in HA-S1P2-transfected and vector-
transfected cells and has no effect on HA-S1P2 expression.  These are representative results of 
three different preparations of cells.    
 
FIGURE 3.  Effects of S1P receptor antagonists and specific S1P receptor siRNA on 
the nuclear translocation of S1P2 and Y416 phoshorylated c-Src.  Vector or HA-S1P2 
transfected MDA-MB-231 were treated with JTE-013, CAY10444, or CYM50367 (all at 10 PM) 
for 4 h and with S1P (5 PM) in the last 1 h or with scrambled or S1P3 or S1P4 specific siRNA 
according to the methods with subsequent addition of S1P for 1 h. (A-E) Nuclei preparations were 
western blotted with anti-HA, anti-c-Src, anti-Y416 phosphorylated c-Src, and anti-lamin 
antibodies.  The western blots show the failure of JTE-013 (A), CAY10444 (B), and S1P3 siRNA 
(C) to induce nuclear translocation of HA-S1P2 and Y416 phosphorylated c-Src.  In (C), the inset 
shows successful knock down of S1P3 mRNA with the S1P3 siRNA as assessed by RT-PCR 
analysis. (D and E) Western blots show nuclear translocation of HA-S1P2 in response to 
CYM50367 (D) and S1P4 siRNA (E), respectively, and inhibition of the effects of CYM50367 
 
with S1P (D).  In (E), the inset shows successful knock down of S1P4 mRNA with the S1P4 siRNA 
as assessed by RT-PCR analysis.  (F) The western blot shows that S1P4 siRNA has no effect on 
HA-S1P2 expression, detected in whole cell lysates.  These are representative results of three 
different preparations of cells.    
 
FIGURE 4.  Effects of SK1 and SK2 inhibitors, S1P receptor antagonists, and specific 
SK isoform siRNA on growth of MDA-MB-231 cells.  Vector or HA-S1P2 transfected MDA-
MB-231 were treated with JTE-013, CAY10444, SKi, RB-005, 55-22, ROMe, or CYM50367 (all 
at 10 PM) for 4 h or with scrambled or SK1 or SK2 specific siRNA.  Cell impedance index was 
used as a measure of cell growth.  The indices were determined for each treatment (* P < 0.05 
versus vector-transfected cells, n = 3). 
 
FIGURE 5.  Schematic showing the functional interaction between (A) SK2 and S1P4 
that regulates the nuclear translocation of S1P2 and (B) between SK2 and nuclear 
translocation of Y416 phosphorylated c-Src. 
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ABBREVIATIONS 
Bcr-Abl1, B-cell receptor-Abelson tyrosine kinase 1; Brms1, breast carcinoma metastasis 
suppressor 1; cyto, cytoplasmic preparation; ER, estrogen receptor; ERM, Ezrin, Radixin, Moesin 
protein; ERK, extracellular signal regulated kinase; GAPDH, glyceraldehyde 3-phosphate 
dehydrogenase; HA, Hemagluttinin; HER2, human epidermal growth factor receptor 2; Nrf2, 
nuclear factor-like 2; Nuc, nucleur preparation; PM, plasma membrane; PP2A, protein phosphatase 
2A; ROMe, (R)-FTY720 methyl ether; S1P, sphingosine 1-phosphate; SKi, 2-(p-hydroxyanilino)-
4-(p-chlorophenyl)thiazole; SK1, sphingosine kinase 1; SK2, sphingosine kinase 2; S1P2, 
sphingosine 1-phosphate receptor-2, S1P3, sphingosine 1-phosphate receptor-3; S1P4, sphingosine 
1-phosphate receptor-4. 
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Supplemental Figure legends 
 
Suppl Figure 1.  Quantification of the effect of SKi on the nuclear localization of HA-tagged S1P2, c-Src 
and Y416 phosphorylated Src (pSrc) in HA-S1P2-transfected MDA-MB-231 cells.  Nuclear HA-S1P2, c-Src 
and pSrc were quantified relative to nuclear lamin levels.  Control levels are set at 100 +/- SEM % and 
results are from n=3 experiments. 
 
Suppl Figure 2.  Quantification of the effect of SKi on Y416 phosphorylated Src (pSrc) levels in cell 
lysates from vector- and HA-S1P2- transfected MDA-MB-231 cells.  pSrc was quantified relative to actin 
levels.  Control levels are set at 100 +/- SEM % and results are from n=3 experiments. 
 
Suppl Figure 3.  Quantification of the effect of SKi on nuclear Y416 phosphorylated Src (pSrc) and c-Src 
levels in vector-transfected MDA-MB-231 cells.  Nuclear c-Src and pSrc were quantified relative to lamin 
levels.  Control levels are set at 100 +/- SEM % and results are from n=3 experiments. 
 
Suppl Figure 4.  Quantification of the effect of SKi on nuclear HA-tagged S1P2 and Y416 phosphorylated 
Src (pSrc) levels in HA-S1P2- transfected MCF-7 cells.  Nuclear HA-tagged S1P2 and pSrc were quantified 
relative to lamin levels.  Control levels are set at 100 +/- SEM % and results are from n=3 experiments. 
 
Suppl Figure 5.  Quantification of the effect of (A) RB-005; (B) 55-22; (C) SK1 siRNA; (D) ROMe; (E) 
SK2 siRNA on the nuclear localization of HA-tagged S1P2 and Y416 phosphorylated Src (pSrc) in HA-
S1P2-transfected MDA-MB-231 cells.  Nuclear HA-S1P2 and pSrc were quantified relative to nuclear lamin 
levels.  Control levels are set at 100 +/- SEM % and results are from n=3 experiments. 
 
Suppl Figure 6.  Quantification of the effect of ROMe on Y416 phosphorylated Src (pSrc) levels in cell 
lysates from vector- and HA-S1P2- transfected MDA-MB-231 cells.  pSrc was quantified relative to actin 
levels.  Control levels are set at 100 +/- SEM % and results are from n=3 experiments. 
 
Suppl Figure 7.  Quantification of the effect of (A) JTE-013; (B) CAY10444; (C) S1P3 siRNA; (D) 
CYM50637; (E) S1P4 siRNA on the nuclear localization of HA-tagged S1P2 and Y416 phosphorylated Src 
(pSrc) in HA-S1P2-transfected MDA-MB-231 cells.  Nuclear HA-S1P2 and pSrc were quantified relative to 
nuclear lamin levels.  Control levels are set at 100 +/- SEM % and results are from n=3 experiments. 
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Background: The role of the sphingosine 1-phosphate receptor-2 in cancer is 
controversial. 
 
Results: Inhibition of sphingosine kinase 2/sphingosine 1-phosphate receptor-4 
promotes nuclear translocation of sphingosine 1-phosphate receptor-2 and reduces 
cancer cell growth. 
 
Conclusion: Sphingosine kinase 2 and sphingosine 1-phosphate receptor-4 participate 
to prevent sphingosine 1-phosphate receptor-2 nuclear localisation. 
 
Significance: The sub-cellular localisation of sphingosine 1-phosphate receptor-2 
determines cancer cell growth. 
